A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience
Frontiers in Public Health April 14, 2026 Anthony L. Back, Bonnie A. Mcgregor, Leslie L. Thorn et al.
Introduction: Psilocybin therapy has demonstrated efficacy for cancer-related anxiety and depression, but resource-intensive individual treatment models raise important questions for psychedelic public health about equitable access and scalability. In our prior Phase 1/2 study of group retreat psilocybin therapy for patients with metastatic cancer, we observed partial responders who did not...